What Lasma Treats: Main Uses and Benefits

Lasma is relevant for use in the management of sustained support for chronic airway diseases. It is commonly applied for the long-term management of conditions like Asthma and Chronic Obstructive Pulmonary Disease (COPD), including the components of Chronic Bronchitis and Emphysema. This foundational therapeutic approach is relevant in conditions characterized by persistent restriction of the bronchial passages.

Relief from Persistent Breathing Difficulties

The medication is commonly used to ease symptom clusters that interfere with daily functioning, specifically addressing the persistent discomfort of wheezing, chest tightness, and shortness of breath. Through its therapeutic focus on the airways, Lasma may assist in maintaining functional stability. This sustained action provides supportive relief that helps patients cope more steadily with these difficult symptomatic manifestations.

Foundation for Long-term Symptom Control

It is primarily used as a prophylactic and maintenance treatment for stable, chronic conditions. Its use may contribute to managing the frequency and intensity of recurring breathing episodes, supporting general well-being and helping maintain a sense of stability in chronic disease management.

“This therapeutic approach is relevant for offering ongoing support that may help maintain stability and ease the overall symptom burden associated with chronic lung issues.”

Therapeutic Context: Managing Persistent Breathing Difficulties Lasma is commonly used as a maintenance therapy to ease the discomfort and strain of recurrent wheezing, chest tightness, and shortness of breath associated with chronic airway restriction.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Lasma?

Official regulatory documents strictly define the populations eligible to use Lasma (Choline Theophyllinate), based on absolute prohibitions and conditions that necessitate caution or restriction.

Absolute Contraindications

Lasma is officially contraindicated and must not be used in individuals with a known hypersensitivity to any xanthine derivatives or in patients with acute cardiac conditions, such as Acute Myocardial Infarction or severe Coronary Artery Disease.

Restricted and Conditional Use

Use is restricted in several populations due to the drug’s clearance profile. Patients with severe Liver Disease (e.g., cirrhosis) or Congestive Heart Failure require extreme caution, as official labels document significantly decreased drug clearance. Caution is also necessary for patients with a history of Seizure Disorders or Active Peptic Ulcer Disease, as the drug may exacerbate these pre-existing conditions.

Age and Reproductive Status

The medicine is approved for use in adults and children, but official labeling requires caution for older adults (over 60 years) and infants (under one year) due to documented changes in drug metabolism. For pregnancy, the drug is classified as Category C, restricting use to situations where the maternal benefit outweighs the potential risk. The medication is also documented to be excreted into breast milk.

Interactions with other medicines and products

Official government regulatory documents classify interactions with Lasma based on their potential to significantly alter the drug's exposure or effect.

Exposure-Modifying Medicinal Products (PK): Concomitant use with strong inhibitors of the cytochrome P450 (CYP) enzyme systems—such as rifampicin and phenytoin—is documented to significantly alter the plasma concentrations of Lasma, necessitating close monitoring. The regulatory labeling explicitly identifies substances that inhibit or induce the metabolism of Lasma, leading to increased or decreased systemic exposure, respectively. For instance, gemfibrozil is specifically listed as a substance that may increase Lasma levels.

Effect-Modifying Medicinal Products (PD): The official profile notes potential for additive effects when Lasma is co-administered with certain other drugs, especially those affecting similar biological pathways. Specific requirements related to timing and separation of administration are documented for certain agents to manage interaction risks.

Non-Medicinal Interactions: Interaction information extends to non-prescription substances. Official documents advise on the need to avoid or monitor the intake of certain herbal products or specific foods that are known to interfere with the drug’s metabolism or absorption, as these can affect Lasma’s overall concentration in the body.

The regulatory interaction structure strictly defines these combinations to ensure the therapeutic activity of Lasma is maintained and to mitigate risks associated with altered drug levels.

The physiological actions of Lasma (Choline Theophyllinate) are executed through multiple distinct molecular pathways within the respiratory system and central nervous system. The active component, Theophylline, engages mechanisms that modulate smooth muscle contractility, inflammatory signaling, and central respiratory drive.

Enzyme Inhibition and Smooth Muscle Relaxation

This core mechanism involves the inhibition of Phosphodiesterase (PDE) enzymes ( PDE3 and PDE4), leading to an increase in intracellular signaling molecules like cAMP. The resulting cascade reduces internal calcium levels in bronchial smooth muscle, resulting in a reduction of bronchial smooth muscle tone. This action also extends to modulating the contractility of the diaphragm.

Adenosine Receptor Antagonism and Drive Modulation

The drug acts as an antagonist to Adenosine Receptors ( A1, A2A, A2B), blocking the action of adenosine on its receptors and reducing the release of pro-constrictive mediators. In the central pathways, this receptor antagonism serves to stimulate the medullary respiratory center.

Regulation of Inflammatory Gene Expression

A separate mechanism involves the indirect activation of the nuclear enzyme Histone Deacetylase 2 ( HDAC2) by suppressing the PI3K- delta pathway. This HDAC2 restoration enables the enzyme to switch off the transcription of genes that produce pro-inflammatory mediators, thereby suppressing pro-inflammatory cytokine and mediator synthesis in the respiratory system.

How to Use Lasma: Administration Guidelines

This section outlines the usage instructions for Lasma (Montelukast), focusing on the procedural requirements for proper administration.

Administration Scope

The approved route of administration for all dosage forms of Lasma is oral. For maintenance treatment, the dose is generally taken once daily in the evening.

Specific Administration Instructions

Timing and Meals: Lasma can generally be taken with or without food. For maintenance therapy, the dose is typically taken in the evening.

For Exercise-Induced Bronchoconstriction (EIB) Prevention: A single dose is taken at least 2 hours before exercise. Patients taking a daily maintenance dose should not take an additional dose for EIB, and no more than one dose for EIB should be taken in a 24-hour period.

Preparation Requirements (Oral Granules): The contents of the oral granule packet must be administered within 15 minutes of opening. Granules can be poured directly into the mouth or mixed with a spoonful of cold or room temperature soft food (such as applesauce, rice, or breast milk/formula). The prepared mixture must be consumed immediately and not stored for later use.

Missed Dose: If a dose is missed, take the next dose at the regular scheduled time. Do not take two doses at the same time.

Research evidence / Overview of Studies for Lasma

The research on Lasma (Choline Theophyllinate) comes from various scientific sources including randomized controlled trials (RCTs), systematic reviews, and long-term observational cohort studies. The evidence was evaluated for its role as a maintenance therapy for chronic conditions characterized by functional limitations in breathing. Findings describe group patterns and contribute to the broader evidence landscape, but research does not determine whether an individual will respond similarly.

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Research has widely examined the use of this drug in adults with stable, moderate-to-severe COPD. Studies focused on changes measured during the study period, applied in studies examining patient-reported experiences. RCTs explored physiological responses, focusing on functional measures such as the Forced Expiratory Volume in 1 second (FEV1). Studies consistently reported patterns of change in these primary lung function markers when compared to a placebo. Research also explored outcomes related to episodic or acute changes, such as the rate of disease exacerbations. Findings for these long-term outcomes were mixed, with some trials monitoring patterns where exacerbation rates did not change when the drug was added to standard inhaled treatments.

Evidence for Use in Chronic Asthma Management

The drug was also evaluated in patients with chronic asthma, particularly those experiencing fluctuating manifestations. Short-term to intermediate-term studies explored outcomes related to overnight constriction of the airways. Findings describe patterns observed where symptoms evolved in the observed populations as reported by patients. However, studies also reported patterns where objective sleep quality was observed alongside measures of wakefulness and drowsiness, indicating potential changes in sleep architecture.

Key Limitations, Gaps, and Uncertainties in the Research Record

The evidence base highlights several limitations that restrict the certainty of findings. Much foundational evidence precedes the widespread adoption of newer, standard-of-care inhaled maintenance medications, which means its current comparative evidence is not fully established by older trials. Furthermore, the long-term impact on outcomes like all-cause mortality has not been sufficiently evaluated, and data for certain groups, such as those with severe disease, remain insufficient in randomized settings.

Common questions about Lasma (FAQ)

Q: What happens if I forget to take a dose of Lasma?

According to the official instructions in the administration guidelines, the procedure for a missed dose describes taking the next scheduled dose at the regular time. It is important to avoid taking two doses at once to compensate for the missed one.

Q: Does Lasma interact with blood thinners?

Official regulatory documents classify drug interactions that can change Lasma's concentration or effect in the body. Regulatory labeling indicates that when Lasma is taken alongside blood thinners, the combination may necessitate close monitoring.

Q: Does Lasma interact with common medications for heartburn or acid reflux?

Official documents describe that Lasma’s systemic exposure, or the amount of drug in the body, may be affected by certain medications used for heartburn or acid reflux. The potential for altered Lasma levels means the combination may require monitoring, as outlined in the official documentation.

Q: Does Lasma interact with birth control pills?

Regulatory information states that certain components found in oral birth control pills can increase the concentration of Lasma in the body. The potential for increased Lasma concentration means that the combination may require blood level monitoring.

Q: What common supplements or vitamins are known to interact with Lasma?

Official interaction documents describe the need to monitor or avoid the intake of certain herbal products or specific foods. This is because they are known to interfere with how the drug is processed by the body.

Q: Can Lasma affect blood pressure readings?

Official safety information includes documented cardiac effects such as rapid heart rate (tachycardia) and palpitations. These effects, as described in regulatory documents, can sometimes be related to changes in blood pressure.

Q: How long does the effect of a single dose of Lasma typically last?

The half-life of Lasma’s active component, which describes the time it takes for half of the dose to be cleared from the body, typically ranges from 3 to 12.8 hours in healthy, non-smoking adults. The half-life data is referenced in regulatory documents to characterize the drug’s behavior for maintenance therapy.

Q: Does Lasma interact with antidepressant medications?

Official interaction documents note that certain antidepressant medications may interact with Lasma. This interaction can alter the drug's concentration or effect in the body and may require monitoring according to official guidelines.

Q: How quickly can someone expect Lasma to start working?

Lasma is indicated for ongoing maintenance therapy, not fast-acting, immediate symptom relief. The active component is rapidly absorbed, reaching peak concentration in the blood within approximately 1 to 2 hours following a dose of an immediate-release form.

Q: What is the difference between Lasma and other medicines for similar conditions?

Lasma is classified as a xanthine derivative and bronchodilator. This distinguishes it from other types of respiratory medicines based on its specific pharmacological class and its core mechanisms of action on the airways.

Q: Does Lasma cause drowsiness or affect alertness?

Official safety information for Lasma's active component includes central nervous system (CNS) effects. Documented side effects include dizziness and drowsiness, as well as stimulating effects like insomnia and irritability.

Q: Is Lasma suitable for long-term use?

Regulatory documents indicate that Lasma is officially intended as a maintenance therapy. The drug is indicated for chronic lung conditions, which supports its long-term use as a maintenance therapy.

Q: Is Lasma considered a controlled substance?

Lasma, which contains Choline Theophyllinate, is not classified as a controlled substance by official government agencies responsible for drug scheduling.

Q: What should be done if someone experiences a severe allergic reaction to Lasma?

A severe allergic reaction is documented as a medical emergency. If signs of a severe allergic reaction (hypersensitivity) occur, immediate emergency medical attention should be sought.

Q: Is it true that Lasma can cause dry mouth?

While dry mouth is not always listed as a common adverse reaction, official safety information documents note that dry mouth has been observed in the context of certain concentrations of the drug's active component.

Q: Is Lasma used for immediate relief or for ongoing management?

Lasma is indicated for ongoing maintenance therapy and is not intended to be used as a fast-acting, immediate-relief medicine for sudden breathing problems or attacks.

Q: Is Lasma recommended for older adults?

Official warnings indicate that caution is advised for older adults, particularly those over 55 or 60. This is due to documented changes in how the drug is processed in this population.

Q: Can Lasma be used during pregnancy, or are there limitations?

Lasma is classified in Pregnancy Category C by the FDA. This classification means official use during pregnancy is restricted to situations where the documented potential maternal benefit outweighs the potential risk to the fetus.

Q: Is there any information about Lasma use during breastfeeding?

Official regulatory documentation confirms that the active component of Lasma is excreted into breast milk. Its presence in breast milk may be associated with mild toxicities, such as irritability, in nursing infants.

Q: Where can I find the official patient information leaflet for Lasma?

The official patient information leaflet or prescribing information for Lasma can be accessed by searching the government databases of drug information. These include resources like NIH DailyMed or the European Medicines Agency (EMA) websites.

Q: Is Lasma approved in countries outside of the US?

The active ingredient in Lasma is documented in international pharmacopeias and has been evaluated by regulatory bodies in multiple countries. This regulatory review supports its availability and use outside of the United States.

Q: What is the role of Lasma in the overall treatment plan for the condition it treats?

Lasma is officially indicated to be used as a maintenance treatment. This means its role is to support sustained airway function as part of a long-term management plan, often used alongside other standard treatments.

Q: Are children eligible to use Lasma?

Official documents state that Lasma is approved for use in certain pediatric age groups, and dosing tables provide administration details for children. However, safety information also includes specific cautions regarding its use in children under 10 years of age for certain formulations.

The storage and disposal of Lasma (Choline Theophyllinate) must strictly adhere to official regulatory requirements to maintain product stability and safety. The medication requires storage at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). The product must not be stored above 30 C and must be protected from both excessive heat and moisture. The official labeling requires that Lasma be kept in its original container, which must be tightly closed. For safety, a mandatory requirement is to store the medicine out of the sight and reach of children. Disposal of any unused or expired product must be executed in accordance with local requirements for pharmaceutical waste and should not be discarded via household trash or wastewater systems.